The Family Heart Foundation, the leading research, education and advocacy organization focused on genetic dyslipidemias, today announced it will share key research findings and data at the 2025 American Heart Association Scientific Sessions in New Orleans on November 7-10. Family Heart Foundation experts will lead poster and oral presentations that highlight novel strategies to accelerate identification of familial hypercholesterolemia (FH), improve diagnosis of FH, and opportunities to improve cholesterol management in individuals with Atherosclerotic Cardiovascular Disease (ASCVD). Family Heart Foundation presentations include:

Moderated Digital Poster

AI-Driven Identification and Outreach for Familial Hypercholesterolemia: Early Results from the FIND FH Initiative at a Single Academic Center

Saturday, Nov. 8 at 1:45-2:55 pm, Population Science Zone

• Moderated Digital Poster 8 highlights efforts and achievements to date from the Family Heart Foundation and Emory University as part of the FIND FH^® initiative, a multi-site collaboration that integrates an artificial intelligence machine learning algorithm into institutional structured electronic medical record to identify patients with high likelihood of having FH.

Digital Poster Presentation

Cholesterol Management in U.S. Individuals with ASCVD within the Family Heart Database^® during 2022/23: Current State of Care and Opportunities for Improvement

Sunday, Nov. 9 at 9:15-10:30 a.m., Population Science Zone

• Moderated Digital Poster 13 discusses substantial gaps between guideline recommended LDL-C management and clinical care among U.S. individuals with ASCVD, especially among women, black individuals, and those under the age of 50.

Oral Presentation

Novel Strategies to FIND People Living with Genetic Dyslipidemias: Results from The Family Heart Foundation Flag, Identify, Network, and Deliver™ Familial Hypercholesterolemia (FIND FH) Collaborative Learning Network

Sunday, Nov. 9 at 3:30-4:45 pm CST, Room 224

• Presentation highlights novel strategies that can accelerate FH identification and improve diagnosis, including leveraging a multi-site collaborative learning approach to successfully identify individuals with FH and prevent risks associated with missed or delayed diagnoses.

In addition, the Family Heart Foundation will host a booth (#3742) with resources and information about genetic dyslipidemias. To learn more about the Family Heart Foundation and its efforts to prevent premature cardiovascular disease, visit FamilyHeart.org.

About the Family Heart Foundation

The Family Heart Foundation is a nonprofit research and advocacy organization. The Foundation is a pioneer in the application of real-world evidence, patient-driven advocacy, and multi-stakeholder education to help prevent heart attacks and strokes caused by familial hypercholesterolemia (FH) and elevated lipoprotein(a), or Lp(a), two common genetic disorders that have an impact across generations. The Family Heart Foundation conducts innovative research to break down barriers to diagnosis and management of inherited lipid disorders; educates patients, providers, and policy makers; advocates for change; and provides hope and support for families impacted by heart disease and stroke caused by FH, HoFH, and elevated Lp(a). The organization was founded in 2011 as the FH Foundation. For more information, visit FamilyHeart.org and follow us on Twitter, Facebook, Instagram and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251106668638/en/

Family Heart Foundation data presented at AHA 2025 highlights novel strategies to accelerate identification of familial hypercholesterolemia (FH), improve diagnosis of FH, and opportunities to improve cholesterol management in individuals with ASCVD.